Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab in Prodromal Alzheimer's Disease (Japan, Phase 3)
jRCT2080223374Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing Solanezumab with Placebo (2 arms). Started Nov 2016; status: completed.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080223374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223374.